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1  | INTRODUC TION
Neuromyelitis optica spectrum disorders (NMOSD) are rare relapsing 
inflammatory diseases of the central nervous system, with optic neu-
ritis (ON) and myelitis as clinical hallmarks of the disease.1 NMOSD 
were distinguished from multiple sclerosis as a separate disease en-
tity in 2014 after the identification of antibodies against aquaporin- 4 
(AQP4- IgG), an astrocytic water channel, in up to 80% of patients.1 
However, to date, NMOSD are characterized by a considerable im-
munological and clinical heterogeneity. The most drastic change in 
the past decade was probably the further separation of the NMO 
spectrum after identification of antibodies against myelin oligoden-
drocyte glycoprotein (MOG) immunoglobulin G (IgG) in a subset of 
AQP4- IgG seronegative patients – now termed MOG- IgG- associated 
disease and regarded as a condition with a pathogenesis and clinical 
presentation distinct from classical AQP4- IgG- associated NMOSD.2
After the initial description of NMOSD, case series and small 
cross- sectional cohort studies contributed significantly to our un-
derstanding of the disease. Key features of NMOSD shown in early 
research were: (i) the highly injurious effects and repetitive charac-
ter of attacks, especially of myelitis, ON and brainstem syndromes; 
(ii) the – often dramatically – negative effects of immunotherapies 
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Abstract
Neuromyelitis optica spectrum disorders are rare relapsing inflammatory central 
nervous system diseases with a heterogenous immunological and clinical spectrum. 
International collaborations are required to: (i) reach a better understanding of the 
disease and its subtypes; (ii) develop laboratory and imaging biomarkers; and (iii) ulti-
mately improve treatments.
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used in multiple sclerosis, such as interferon- beta and natalizumab, 
whereas in contrast, B- cell depleting drugs are very effective; and 
(c) the significant heterogeneity of the disease spectrum, including 
epileptic seizures, narcolepsy and even chronic progressive disease 
courses.3,4 In particular, this heterogeneity and the rarity of NMOSD 
led to many conflicting results on: (i) the expected range of damage 
for initial and following attacks; (ii) the existence of a progressive 
disease component; and (iii) the efficacy of off- label treatments for 
relapse prevention. It is also still unclear, why the incidence differs 
so dramatically between different geographic regions, with a lower 
incidence in Europe and North America, and a higher incidence in 
Eastern Asia.5 Only larger longitudinal studies can solve these ques-
tions. To reach this ultimate goal, national and international collabo-
rations are required.
2  | CURRENT COLL ABOR ATIONS
Early in NMOSD research, national registry studies, such as the 
German Neuromyelitis optica Study Group (NEMOS), were founded 
to improve research on epidemiology and clinical course in NMOSD, 
as well as to collect biomaterials and establish common recommen-
dations for diagnosis and treatment.6 Shortly after, European and 
international NMOSD networks and registers were founded. These 
networks contributed extremely valuable work improving our un-
derstanding of the disease; for example, by describing the influence 
of sex on clinical aspects, clinical work- up of attacks and by studying 
the effects of acute therapy of relapses underlining the importance 
of early plasma separation/immune adsorption.7,8 Subsequent to the 
seminal discovery of AQP4- IgG as a specific biomarker of NMOSD, 
joint expert statements from these networks on monitoring and 
treatment, and the increased awareness for the disease have been 
instrumental for a fast- tracked improvement of clinical care and ini-
tiation of clinical trials.6 However, the mostly cross- sectional charac-
ter of the studies carried out and their ethnic homogeneity limits the 
generalizability of these studies. Further problems arise from heter-
ogenous acquisition protocols and the lack of source data, especially 
for imaging studies describing lesion sites in the optic nerve, spinal 
cord and – to a smaller extent – brain.
An international NMOSD network, which has to be mentioned, is 
the Guthy- Jackson Charitable Foundation, bringing together experts 
for scientific conferences and projects since 2008. Guthy- Jackson 
Charitable Foundation fostered international collaborations and made 
many multicenter studies possible.9 Two interesting approaches, 
which we had the honor to participate in, were the collaborative op-
tical coherence tomography (OCT) study in NMOSD (CROCTINO), 
quantifying damage in the retina, and the parallel study on magnet 
resonance imaging (PAMRINO), quantifying damage in the brain and 
spinal cord.10 CROCTINO included 539 patients at 22 participating 
centers (North and South America, Europe, Asia), and is thereby the 
largest image repository in NMOSD required so far. Longitudinal 
data were available for 157 patients from 11 centers. CROCTINO 
is the first study in NMOSD including this amount of OCT source 
data across multiple nations and ethnicities, and will assist in solving 
many of the outstanding questions in NMOSD research, such as the 
exact magnitude of ON- related retinal damage and associated func-
tional changes in different NMOSD subtypes, the existence of ON- 
independent damage in NMOSD, and the influence of therapies and 
ethnicities on clinical course and disability accumulation. However, 
CROCTINO and PAMRINO also have their limitations, including: 
(i) the retrospective data acquisition in often heterogeneous study 
protocols, and with different OCT and magnet resonance imaging 
devices; and (ii) the lack of age- and sex- matched healthy controls 
from all study sides. However, CROCTINO and PAMRINO estab-
lished the foundation for future prospective studies of comparable 
size including the creation of: (i) a strong and productive collaborative 
research community; (ii) a feasible study protocol adapted to NMOSD 
patients; and (iii) evidence- based outcome parameters not only for 
observational, but also for future, therapeutic trials.
3  | CONCLUSIONS AND FUTURE AC TION
CROCTINO and PAMRINO have built the basis for an international 
NMOSD image repository, which is currently being developed. Also, 
on a national level, prospective collaborative studies have been de-
ployed; for example, the NationNMO cohort in Germany. NMOSD 
is thereby an example of a rare disease, for which collaborative re-
search can achieve unprecedented scientific progress in a very lim-
ited time frame. Last year, three therapeutic targets were approved 
as the first US Food and Drug Administration- approved treatments 
for NMOSD, and our joint scientific work not only led to a better 
understanding of NMOSD as a whole, but also to a further separa-
tion of the disease spectrum, including the evidence- based differen-
tiation of AQP4- IgG seropositive patients and MOG- IgG- associated 
disease patients, which will ultimately allow better care and treat-
ment of the individual patient. In the future, further large collabo-
rative efforts should focus on the acquisition of longitudinal and 
especially prospective data to: (i) confirm disease characteristics and 
damage pattern previously shown in retrospective data; (ii) establish 
NMOSD- specific biomarkers and end- points, including imaging end- 
points, for clinical trials; and (iii) build the basis for fast and success-
ful multicentric clinical treatment trials to avoid disability accrual and 
improve the life of patients with NMOSD.
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